Description: CSPC Pharmaceutical Group Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Antibiotics, Vitamin C, and Caffeine and Others segments. It offers NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Xuanning for hypertension; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; Ailineng for nerve glioma and brain metastases, and adjuvant treatment of malignant pleural and peritoneal effusion; and Nuolining for chronic myelocytic and acute lymphoblastic leukemia. The company also provides generic drugs, including Ouyi for anti-inflammatory, Gubang to treat osteoporosis, and Weihong for various infections, as well as Guoweikang, a vitamin C supplement tablets; traditional Chinese medicine; and antibiotics comprising Amoxicillin and Ampicillin capsules, Ceftriaxone and Cefazolin sodium injections, and Meropenum injections. In addition, the company offers antibiotics, vitamin C, and caffeine APIs; and researches and develops various products with focus on the therapeutic areas of cardio-cerebrovascular diseases, metabolic diseases, oncology, psychiatry, and neurology. Further, it provides property holding, storage, sourcing, and distribution services; and sewage products and by-products. The company has a co-development and strategic collaboration agreement with Shanghai Junshi Biosciences Co., Ltd.; and strategic partnership with I-Mab Biopharma. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. The company was founded in 1997 and is headquartered in Shijiazhuang, the People's Republic of China.
Home Page: www.cspc.com.hk
No. 226 Huanghe Street
Shijiazhuang,
050035
China
Phone:
86 31 1870 37015
Officers
| Name | Title |
|---|---|
| Mr. Dongchen Cai | Exec. Chairman |
| Mr. Cuilong Zhang | Vice-Chairman & CEO |
| Mr. Chunlei Li | Exec. Director & Chief Scientist |
| Mr. Kin Man Chak | Exec. Director |
| Mr. Weidong Pan | Exec. Director |
| Mr. Huaiyu Wang | Exec. Director |
| Mr. Zhenguo Wang | Exec. Director |
| Dr. Qingxi Wang | Exec. Director |
| Dr. Hao Jiang | Exec. Director |
| Mr. Jinxu Wang | Sr. VP |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 14.4092 |
|---|---|
| Trailing PE: | 16.5714 |
| Price-to-Book MRQ: | 3.4133 |
| Price-to-Sales TTM: | 0.4467 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 24746 |